HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cardioplegic Solutions

Solutions which, upon administration, will temporarily arrest cardiac activity. They are used in the performance of heart surgery.
Also Known As:
Cardioplegic Solution; Solution, Cardioplegic; Solutions, Cardioplegic
Networked: 577 relevant articles (56 outcomes, 51 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Long, Cun: 4 articles (09/2007 - 06/2002)
2. Dieterlen, Maja-Theresa: 3 articles (09/2021 - 01/2019)
3. Hoyer, Alexandro: 3 articles (09/2021 - 01/2019)
4. Movsesyan, R R: 3 articles (07/2020 - 01/2007)
5. Salameh, Aida: 3 articles (01/2020 - 11/2016)
6. Alves, Marco G: 3 articles (11/2011 - 12/2009)
7. Carvalho, Rui A: 3 articles (11/2011 - 12/2009)
8. Oliveira, Paulo J: 3 articles (11/2011 - 12/2009)
9. Pisarenko, O I: 3 articles (04/2006 - 01/2003)
10. Shul'zhenko, V S: 3 articles (04/2006 - 01/2003)

Related Diseases

1. Ischemia
2. Reperfusion Injury
3. Hypothermia
4. Heart Arrest (Cardiac Arrest)
5. Stroke (Strokes)
04/01/1993 - "In relation to the group with cardioplegic solution alone, postischemic aortic flow, coronary flow, cardiac output, and stroke work were all significantly greater (p < 0.05) in the group with the receptor antagonist (aortic flow: 49.5 +/- 2.4 versus 29.4 +/- 3.3 ml/min; coronary flow; 12.4 +/- 1.2 versus 8.5 +/- 1.3 ml/min; cardiac output, 62.0 +/- 2.8 versus 38.0 +/- 4.4 ml/min; stroke work, 12.6 +/- 0.8 versus 7.1 +/- 0.8 cm H2O.ml). "
04/01/1993 - "Within the group protected by cardioplegic solution alone, postischemic aortic flow, coronary flow, cardiac output, and stroke work were all significantly decreased (p < 0.05) compared with preischemic values (aortic flow, 50.8 +/- 2.7 versus 29.4 +/- 3.3 ml/min; coronary flow, 13.2 +/- 1.3 versus 8.5 +/- 1.3 ml/min; cardiac output, 64.0 +/- 3.8 versus 38.0 +/- 4.4 ml/min; stroke work, 12.5 +/- 0.7 versus 7.1 +/- 0.8 cm H2O.ml). "
10/01/1999 - "Compared with the protection afforded by blood cardioplegic solution without L-arginine (group 1), the addition of a 4 mmol/L concentration of L-arginine (group 2) significantly improved myocardial protection, resulting in complete return of systolic function (end-systolic elastance 38% vs 100%; P <.001 vs 4 mmol/L L-arginine) and preload recruitable stroke work (40% vs 100%; P <. "
02/01/1995 - "The results showed improved early recovery of preload recruitable stroke work area, but not of maximal elastance, after reperfusion of ischemic hearts with warm resuscitative blood cardioplegic solution enhanced with amino acids. "
10/01/1999 - "Unmodified blood cardioplegic solution (group 1) was unable to protect the severely stressed myocardium, resulting in depressed systolic function (39% +/- 1%) and preload recruitable stroke work (40% +/- 1%), increased diastolic stiffness (239% +/- 3%), and high conjugated diene production, myeloperoxidase activity, and coronary vascular resistance. "

Related Drugs and Biologics

1. Magnesium
2. Calcium
3. Adenosine Triphosphate (ATP)
4. Oxygen (Dioxygen)
5. Glucose (Dextrose)
6. Potassium
7. Adenosine (Adenocard)
8. Solutions
9. Arginine (L-Arginine)
10. Krebs-Henseleit solution

Related Therapies and Procedures

1. Cardiopulmonary Bypass (Heart-Lung Bypass)
2. Induced Heart Arrest (Cardioplegia)
3. Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4. Thoracotomy
5. Heart Transplantation (Grafting, Heart)